These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38565692)
1. Time for a new approach to drug development for rare systemic autoinflammatory diseases. Zitoun NM; Demirkaya E; Goldbach-Mansky R; Romano M Nat Rev Rheumatol; 2024 Jun; 20(6):317-318. PubMed ID: 38565692 [No Abstract] [Full Text] [Related]
2. Editorial: Switching to biological agents in autoimmune and autoinflammatory disorders: current targets and therapy. Gasparyan AY Curr Med Chem; 2015; 22(16):1890-1. PubMed ID: 25693591 [No Abstract] [Full Text] [Related]
3. Controlling inflammation: contemporary treatments for autoinflammatory diseases and syndromes. Sterba G; Sterba Y Dermatol Clin; 2013 Jul; 31(3):507-11. PubMed ID: 23827252 [TBL] [Abstract][Full Text] [Related]
8. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Havnaer A; Han G Am J Clin Dermatol; 2019 Aug; 20(4):539-564. PubMed ID: 30997665 [TBL] [Abstract][Full Text] [Related]
9. Introduction to autoinflammatory syndromes and diseases. Abramovits W; Oquendo M Dermatol Clin; 2013 Jul; 31(3):363-85. PubMed ID: 23827242 [TBL] [Abstract][Full Text] [Related]
10. JAK inhibition in the type I interferonopathies. Crow YJ; Neven B; Frémond ML J Allergy Clin Immunol; 2021 Oct; 148(4):991-993. PubMed ID: 34375617 [No Abstract] [Full Text] [Related]
12. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary. Butler D; Shinkai K Dermatol Clin; 2013 Jul; 31(3):427-35. PubMed ID: 23827245 [TBL] [Abstract][Full Text] [Related]
13. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. de Koning HD; Schalkwijk J; van der Meer JW; Simon A J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363 [No Abstract] [Full Text] [Related]
14. The body against self: autoinflammation and autoimmunity. Borella E; Palma L; Zen M; Bettio S; Nalotto L; Gatto M; Domeneghetti M; Laccarino L; Punzi L; Doria A Isr Med Assoc J; 2014 Oct; 16(10):608-10. PubMed ID: 25438443 [No Abstract] [Full Text] [Related]
15. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289 [TBL] [Abstract][Full Text] [Related]
18. Autoinflammatory conditions: when to suspect? How to treat? Grateau G; Duruöz MT Best Pract Res Clin Rheumatol; 2010 Jun; 24(3):401-11. PubMed ID: 20534373 [TBL] [Abstract][Full Text] [Related]
19. [Autoinflammatory diseases]. Mosdósi B; Tóth B Orv Hetil; 2018 Jun; 159(23):898-907. PubMed ID: 29860887 [TBL] [Abstract][Full Text] [Related]
20. Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. Spicer P; Runkel L Expert Opin Investig Drugs; 2019 Feb; 28(2):99-106. PubMed ID: 30661473 [No Abstract] [Full Text] [Related] [Next] [New Search]